Lin MH, et al. Real-world brigatinib use in non-small cell lung cancer patients with prior use of crizotinib/other ALK therapies in the US. Abstract P2.16-09. WCLC 2019, 7-10 sept. Barcelona, Spanje.
Bevolkingsonderzoek darmkanker leidt bij 3,6 procent tot diagnose
okt 2014